Literature DB >> 16394311

Drotrecogin alfa (activated) in severe sepsis.

Jan O Friedrich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16394311     DOI： 10.1056/NEJMc052759

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  An update on activated protein C (xigris) in the management of sepsis.

Authors:  Cesar Alaniz
Journal:  P T       Date:  2010-09

2.  When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).

Authors:  Christian J Wiedermann
Journal:  Intensive Care Med       Date:  2006-03-01       Impact factor: 17.440

3.  How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  Intensive Care Med       Date:  2008-05-27       Impact factor: 17.440

Review 4.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.

Authors:  Hartmut Weiler; Wolfram Ruf
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

5.  Current role of activated protein C therapy for severe sepsis and septic shock.

Authors:  Philip S Barie
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

6.  Medical guidelines and performance measures: the need to keep them free of industry influence.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Mens Sana Monogr       Date:  2008-01

7.  Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death.

Authors:  Sanjay Gupta; Eric B Milbrandt; Lakshmipathi Chelluri
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 8.  Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

Authors:  Jan O Friedrich; Neill K J Adhikari; Maureen O Meade
Journal:  Crit Care       Date:  2006-06-02       Impact factor: 9.097

9.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15

10.  Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.

Authors:  Vania Costa; James M Brophy
Journal:  BMC Anesthesiol       Date:  2007-06-25       Impact factor: 2.217
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.